Tags

Type your tag names separated by a space and hit enter

Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
Blood. 1994 Oct 15; 84(8):2597-603.Blood

Abstract

CD28 and CD40 are important activation pathways for T and B lymphocytes, respectively. The aim of this study was to determine the phenotype of plasma cells (PCs) and the expression of these two molecules, CD28 and CD40. Therefore, we have compared their expression on normal PCs from bone marrows and tonsils with that of freshly explanted malignant PCs from 31 patients with multiple myeloma (MM) and those from 12 human myeloma cell lines. For this purpose, we first described a new approach to identify plasma cells in bone marrow using two-color immunofluorescence analysis with anti-CD38 and B-B4 antibodies. B-B4 specifically recognizes all PC; all B-B4 cells are located within the CD38 bright fraction and vice versa. CD19 and CD56 expression, which was previously shown to discriminate normal from malignant PCs, was also evaluated. In the current report, we show that normal PCs express CD19, CD40, and CD56 (weakly as a subset) and lack CD28. Regardless of whether they express CD19, CD56 is clearly upregulated during the medullary chronic and accelerated phases of MM, but is absent in patients with extramedullary involvement. Although the level of CD40 expression is variable, only patients in accelerated phases expressed high CD40 levels. Finally, whereas CD28 was negative in chronic phase (as in normal PCs), it was expressed in 63% of the patients in accelerated phases and 100% of cell lines. Our data strongly suggest that both disease activity and medullary homing (or not) are correlated with the expression of CD19, CD40, CD28, and CD56 on human myeloma cells.

Authors+Show Affiliations

Laboratoire d'Oncogénèse Immunohématologique, Institut de Biologie, Nantes, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7522634

Citation

Pellat-Deceunynck, C, et al. "Expression of CD28 and CD40 in Human Myeloma Cells: a Comparative Study With Normal Plasma Cells." Blood, vol. 84, no. 8, 1994, pp. 2597-603.
Pellat-Deceunynck C, Bataille R, Robillard N, et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood. 1994;84(8):2597-603.
Pellat-Deceunynck, C., Bataille, R., Robillard, N., Harousseau, J. L., Rapp, M. J., Juge-Morineau, N., Wijdenes, J., & Amiot, M. (1994). Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood, 84(8), 2597-603.
Pellat-Deceunynck C, et al. Expression of CD28 and CD40 in Human Myeloma Cells: a Comparative Study With Normal Plasma Cells. Blood. 1994 Oct 15;84(8):2597-603. PubMed PMID: 7522634.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. AU - Pellat-Deceunynck,C, AU - Bataille,R, AU - Robillard,N, AU - Harousseau,J L, AU - Rapp,M J, AU - Juge-Morineau,N, AU - Wijdenes,J, AU - Amiot,M, PY - 1994/10/15/pubmed PY - 1994/10/15/medline PY - 1994/10/15/entrez SP - 2597 EP - 603 JF - Blood JO - Blood VL - 84 IS - 8 N2 - CD28 and CD40 are important activation pathways for T and B lymphocytes, respectively. The aim of this study was to determine the phenotype of plasma cells (PCs) and the expression of these two molecules, CD28 and CD40. Therefore, we have compared their expression on normal PCs from bone marrows and tonsils with that of freshly explanted malignant PCs from 31 patients with multiple myeloma (MM) and those from 12 human myeloma cell lines. For this purpose, we first described a new approach to identify plasma cells in bone marrow using two-color immunofluorescence analysis with anti-CD38 and B-B4 antibodies. B-B4 specifically recognizes all PC; all B-B4 cells are located within the CD38 bright fraction and vice versa. CD19 and CD56 expression, which was previously shown to discriminate normal from malignant PCs, was also evaluated. In the current report, we show that normal PCs express CD19, CD40, and CD56 (weakly as a subset) and lack CD28. Regardless of whether they express CD19, CD56 is clearly upregulated during the medullary chronic and accelerated phases of MM, but is absent in patients with extramedullary involvement. Although the level of CD40 expression is variable, only patients in accelerated phases expressed high CD40 levels. Finally, whereas CD28 was negative in chronic phase (as in normal PCs), it was expressed in 63% of the patients in accelerated phases and 100% of cell lines. Our data strongly suggest that both disease activity and medullary homing (or not) are correlated with the expression of CD19, CD40, CD28, and CD56 on human myeloma cells. SN - 0006-4971 UR - https://www.unboundmedicine.com/medline/citation/7522634/Expression_of_CD28_and_CD40_in_human_myeloma_cells:_a_comparative_study_with_normal_plasma_cells_ L2 - https://medlineplus.gov/multiplemyeloma.html DB - PRIME DP - Unbound Medicine ER -